X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INI-822 is a small molecule oral inhibitor which works by targeting HSD17B13, it is being investigated for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): INI-822
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: INI-822
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
INI-822 a small molecule inhibitor of HSD17B13, data showed favorable drug properties and in vivo changes in lipid metabolism consistent with those observed with protective forms of HSD17B13.
Lead Product(s): INI-822
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: INI-822
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Inipharm will use the Series A funding to push the lead program — which targets the HSD17B13 gene —through IND filing and into the clinic.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
